Your browser doesn't support javascript.
loading
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Allain, Eric P; Rouleau, Michèle; Vanura, Katrina; Tremblay, Sophie; Vaillancourt, Joanie; Bat, Vincent; Caron, Patrick; Villeneuve, Lyne; Labriet, Adrien; Turcotte, Véronique; Le, Trang; Shehata, Medhat; Schnabl, Susanne; Demirtas, Dita; Hubmann, Rainer; Joly-Beauparlant, Charles; Droit, Arnaud; Jäger, Ulrich; Staber, Philipp B; Lévesque, Eric; Guillemette, Chantal.
Afiliação
  • Allain EP; Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Québec, QC, Canada.
  • Rouleau M; Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Québec, QC, Canada.
  • Vanura K; Division of Hematology and Hemostaseology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Tremblay S; Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Québec, QC, Canada.
  • Vaillancourt J; Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Québec, QC, Canada.
  • Bat V; Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Québec, QC, Canada.
  • Caron P; Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Québec, QC, Canada.
  • Villeneuve L; Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Québec, QC, Canada.
  • Labriet A; Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Québec, QC, Canada.
  • Turcotte V; Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Québec, QC, Canada.
  • Le T; Division of Hematology and Hemostaseology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Shehata M; Division of Hematology and Hemostaseology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Schnabl S; Division of Hematology and Hemostaseology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Demirtas D; Division of Hematology and Hemostaseology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Hubmann R; Division of Hematology and Hemostaseology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Joly-Beauparlant C; CHU de Québec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, Québec, QC, Canada.
  • Droit A; CHU de Québec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, Québec, QC, Canada.
  • Jäger U; Division of Hematology and Hemostaseology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Staber PB; Division of Hematology and Hemostaseology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Lévesque E; CHU de Québec Research Centre, Department of Medicine, Faculty of Medicine, Laval University, Québec, QC, Canada.
  • Guillemette C; Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, Québec, QC, Canada. chantal.guillemette@crchudequebec.ulaval.ca.
Br J Cancer ; 123(2): 240-251, 2020 07.
Article em En | MEDLINE | ID: mdl-32418995
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Antígenos de Histocompatibilidade Menor / Glucuronosiltransferase / Biomarcadores Farmacológicos Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Antígenos de Histocompatibilidade Menor / Glucuronosiltransferase / Biomarcadores Farmacológicos Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article